Citations (1)
Keep up to date with the latest research on this topic with citation updates for this article.
Future Oncology
Volume 18, 2022 - Issue 12
Research Article
Biomarker Subset Analysis of a Phase IIIb, Open-Label Study of Afatinib in EGFR Tyrosine Kinase Inhibitor-Naive Patients with EGFRm+ Non-Small-Cell Lung Cancer
, , , , 
, , , , , , & show all
Jianchun Duan2 Molecular Oncology, Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,
Panjiayuannanli Number 17, Chaoyang District,, Beijing100121, Chinahttps://orcid.org/0000-0003-3300-1707View further author information
https://orcid.org/0000-0003-3300-1707View further author information, , Zhiyi Xue3 Boehringer Ingelheim (China) Investment Co., Ltd, 29/F Park Place,
1601 Nanjing Road (West), Jingan District, Shanghai, 200040, Chinahttps://orcid.org/0000-0002-1357-202XView further author information
https://orcid.org/0000-0002-1357-202XView further author information, , Agnieszka Cseh4 Boehringer Ingelheim International GmbH,
Binger Strasse 173, Ingelheim, 55216, Germanyhttps://orcid.org/0000-0002-9815-2453View further author information
https://orcid.org/0000-0002-9815-2453View further author information, , Yi-Long Wu6 Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences,
106 Zhongshan 2nd Road, Guangzhou, 510080, Chinahttps://orcid.org/0000-0002-3611-0258View further author information
https://orcid.org/0000-0002-3611-0258View further author information & Jie Wang7 Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,
Panjiayuannanli Number 17, Chaoyang District, Beijing, 10021, ChinaCorrespondence[email protected]
https://orcid.org/0000-0002-5602-0487View further author information
https://orcid.org/0000-0002-5602-0487View further author information show all